ReShape Lifesciences (RSLS) announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share. Gross proceeds from the offering are expected to be approximately $2.6M before deducting placement agent fees and other offering expenses. The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions. Maxim Group is acting as sole placement agent in connection with the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RSLS:
- ReShape Lifesciences announces EU MDR certification for European, UK portfolio
- ReShape Lifesciences Faces Nasdaq Delisting Notice
- ReShape Lifesciences Announces Equity Distribution Agreement
- ReShape Lifesciences Announces Merger with Vyome Therapeutics
- ReShape Lifesciences reports Q1 EPS $18.98 vs. ($135.37) last year